Cooper Companies Inc (COO) Q2 2026 Earnings Call Transcript

Why It Matters

Stronger profitability and cash generation give Cooper flexibility to invest in high‑margin lens innovations, return capital to shareholders, and navigate regional headwinds, while raised guidance signals confidence in sustained growth for both vision‑care and fertility businesses.

Key Takeaways

• Consolidated revenue $1.024B, +6.2% YoY.
• Operating margin 26.9%, non‑GAAP EPS $1.10 (+20%).
• Free cash flow $159M; $92M buyback, debt down.
• MyDay lenses drive 7% growth; MiSight up 23%.
• Asia‑Pac vision sales down 4%; strategic review ongoing.

Pulse Analysis

Cooper Companies delivered a robust financial quarter, posting $1.024 billion in consolidated revenue—a 6.2% year‑over‑year increase—and lifting operating margin to 26.9%. Non‑GAAP earnings per share climbed 20% to $1.10, while free cash flow of $159 million funded a $92 million share repurchase and further debt reduction, bringing net debt to $2.4 billion. The company also extended a $950 million tranche of its term loan to 2031, improving liquidity and giving management additional runway for strategic investments.

The earnings beat was anchored by strong performance in the CooperVision segment, where daily silicone hydrogel lenses under the MyDay brand grew 7% and the MiSight myopia‑control line surged 23%. These premium products helped the vision business outpace the broader market and reinforced Cooper’s eighteenth consecutive year of market‑share gains. However, Asia‑Pacific sales slipped 4% as legacy hydrogel demand in Japan weakened, prompting leadership to accelerate product launches, expand distribution capacity, and increase marketing spend to reverse the trend.

Looking ahead, the company raised its FY2026 revenue outlook to $4.3‑$4.35 billion and lifted non‑GAAP EPS guidance to $4.58‑$4.66, reflecting confidence in continued organic growth of 4.5%‑5.5% across both vision and surgical businesses. A strategic review remains active, signaling potential portfolio reshaping that could further enhance returns. While geopolitical uncertainty in the Middle East and competitive pressure on the PARAGARD IUD pose risks, the combination of disciplined cost control, technology‑driven efficiencies, and a strong cash‑generation profile positions Cooper Companies to capitalize on expanding demand for premium contact lenses and fertility solutions.